Invivyd (IVVD) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Protara Therapeutics (TARA) has outperformed Invivyd (IVVD) over the past year, losing 68.6% versus a loss of 83.5%. Over five years, TARA leads with a -67.8% price change compared with -98.4% for IVVD. Protara Therapeutics is the larger company by market cap ($140.4 million vs $122.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVVD | TARA |
|---|---|---|
| Share price | $0.4127 | $2.28 |
| Market cap | $122.01M | $140.38M |
| 1-day change | -7.45% | -5.00% |
| YTD return | -83.29% | -57.22% |
| 1-year return | -83.49% | -68.60% |
| 5-year return | -98.36% | -67.80% |
| EPS (TTM) | $-0.38 | $-1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $53.43M | — |
| Revenue growth (YoY) | +110.47% | — |
| Net income (latest FY) | $-52.49M | $-57.44M |
| Operating margin | -103.99% | — |
| Net margin | -98.25% | — |
| 52-week high | $3.01 | $7.82 |
| 52-week low | $0.4127 | $2.09 |
| Distance from 52-week high | -86.29% | -70.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +2323.07% | +1010.96% |
| Average volume | 5.20M | 1.07M |
| Shares outstanding | 295.63M | 61.57M |
| Employees | 122 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TARA has outperformed IVVD by 14.9 percentage points over the past year.
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
IVVD vs TARA FAQ
Which is bigger, Invivyd or Protara Therapeutics?
Protara Therapeutics (TARA) is larger, with a market capitalization of $140.38M compared with $122.01M for Invivyd (IVVD).
Which stock has performed better over the past year, IVVD or TARA?
TARA returned -68.60% over the past 12 months, compared with -83.49% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Invivyd and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.